About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in ...

New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients?

An analysis of more than 250,000 older adults diagnosed with metastatic non-small cell lung cancer showed only about half ...

New therapies like T-cell engagers and antibody-drug conjugates are showing survival gains in pretreated small cell lung cancer, offering new options after years of limited progre ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...

The European Medicines Agency (EMA) recommended eight medicines for approval this month, including two cancer drugs for treating non-small cell lung cancer (NSCLC). The regulatory body's Committee for ...

Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...

A major analysis of over 250,000 older adults with metastatic non-small cell lung cancer found that fewer than half received systemic treatment, despite advances in targeted and immunotherapies. The ...

Lung adenocarcinoma is the most common type of lung cancer diagnosed in the U.S. Just over half of all non-small-cell lung cancers (NSCLCs) are adenocarcinomas. Finding out that you're at risk of lung ...

After his diagnosis with extensive stage small cell lung cancer, Marcus leaned on his community while exploring treatment ...